Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post' - 2What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- 3Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- 4NAFFIC, AWARE claim first China-EU DPP for textiles
- 5The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
- 4K televisions for Extreme Film Watching Experience
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- Support Your Investment funds with These Individual accounting Thoughts
- The most effective method to Recognize a Great Lab Jewel
- Irish defence minister's trip to Lebanon cancelled
- The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- Don't miss the waxing moon swing by the Beehive star cluster March 27
